Targeting TTR amyloidosis at its source.

Phil, 71, retired; ATTRwt-CM patient

Transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs. Eidos Therapeutics is working to change that by researching ways to treat TTR at its source.

Link to: Patient StoriesLink to: About Amyloidosis